199 research outputs found
O Instrumento Relacional da Investigação em Arte: Apoiando participantes e pesquisadores de origens nĂŁo-artĂsticas para se engajarem na a/r/ tografia
This article argues the potential for a / r / tographic inquiry within sport and exercise research contexts, and outlines how a relational art inquiry tool (RAIT) was developed to support non-Arts background participants to enact a / r / tography. Prior to this investigation, a / r / t / ography methodology has been primarily used within social science and arts contexts, with qualitative sport and exercise researchers yet to employ the approach. Due to the embodied ways of knowing and evocative potential integral to a / r / tographic research, this research sought to devise a set of guiding tools that could be used to support researchers and participants from non-Arts backgrounds. This was done as a way of assisting them to see and find ways to visually articulate complexity, uncertainty and potential 'unseens' occurring within storied accounts. Development of the RAIT tool is informed by a diverse range of theory and ideas underpinning a / r / tography methodology (Irwin, 2004), Gallas' elements of inquiry (2011) and Hetland's Studio Habits of Mind (2013). In this paper, we present the results of the RAIT tool and the results obtained in this study. The results of this study are presented in the following section.Este artigo debate o potencial para uma investigação a/r/togrĂĄfica dentro dos contextos do esporte e da pesquisa de exercĂcios. Ele descreve como um Instrumento Relacional de Investigação em Arte (IRIA) foi desenvolvido para auxiliar participantes fora do campo das artes a realizar a a/r/tografia. Antes desta investigação, a metodologia a/r/togrĂĄfica foi usada principalmente nos contextos de CiĂȘncias Sociais e Artes, jĂĄ com pesquisadores de esporte e exercĂcio qualitativo ainda nĂŁo empregaram esta abordagem. Devido Ă s formas incorporadas de conhecimento e o potencial evocativo uma investigação a/r/togrĂĄfica, esta pesquisa procurou elaborar um conjunto de instrumentos orientadores que poderiam ser usados para apoiar pesquisadores e participantes a se envolverem com a a/r/tografia. Isso foi feito como uma forma de ajudĂĄ-los a ver e encontrar maneiras de articular a complexidade, a incerteza e o potencial do ânĂŁo vistoâ ocorrendo em narrativas. O desenvolvimento da ferramenta RAIT Ă© baseado em uma gama diversificada de teoria e ideias que sustentam a metodologia a/r/togrĂĄfica (IRWIN,2004), os elementos de indagação de Gallas (2011) e os hĂĄbitos da mente de Hetland (2013). Ao abraçar o potencial a/r/togrĂĄfico dentro de um contexto de pesquisa de esporte e exercĂcio, este artigo ilustra como a ferramenta RAIT foi desenvolvida e depois testada para cultivar compreensĂ”es transformadoras e interpretação da cultura da natação atravĂ©s de um proocesso de desenvolvimento relacional e criativo
Evaluation of novel epibatidine analogs in the rat nicotine drug discrimination assay and in the rat chronic constriction injury neuropathic pain model
Nicotine is the primary psychoactive component responsible for maintaining tobacco dependence in humans. Chronic pain is often a consequence of tobacco-related pathologies, and the development of a dual therapeutic that could treat chronic pain and tobacco dependence would be advantageous. Epibatidine reliably substitutes for nicotine in the drug discrimination assay, and is a potent analgesic, but has a side-effect profile that limits its therapeutic potential. Thus, considerable efforts to produce epibatidine derivatives are underway. Here we tested three epibatidine derivatives, 2âČ-fluoro-3'-(4-nitrophenyl)deschloroepibatidine (RTI-7527-102; i.e., RTI-102), 2âČ-fluorodeschloroepibatidine (RTI-7527-36; i.e., RTI-36), and 3'-(3âł-dimethylaminophenyl)-epibatidine (RTI-7527-76; i.e., RTI-76) in both the rat nicotine drug discrimination assay as well as in the rat chronic constriction injury (CCI) of the sciatic nerve neuropathic pain model. Male and female Sprague-Dawley rats were trained on a fixed-ratio 10 schedule to discriminate nicotine (0.32 mg/kg base) from vehicle. All compounds dose-dependently substituted for nicotine, without significant decreases in response rates. In the discrimination assay the rank order potency was RTI-36 > nicotine > RTI-102 > RTI-76. Evidence suggests the α4ÎČ2* subtype is particularly important to nicotine-related abuse potential. Thus, here we utilized the antagonist dihydro-ÎČ-erythroidine (DHÎČE) to examine relative ÎČ2 subunit contribution. DHÎČE (3.2 mg/kg, s.c.) antagonized the discriminative stimulus effects of nicotine. However, relative to antagonism of nicotine, DHÎČE produced less antagonism of RTI-102 and RTI-76 and greater antagonism of RTI-36. It is likely that at nicotinic receptor subunits RTI-102, RTI-76 and RTI-36 possess differing activity. To confirm that the full discriminative stimulus of these compounds was due to nAChR activity beyond the ÎČ2 subunit, we examined these compounds in the presence of the non-selective nicotinic receptor antagonist mecamylamine. Mecamylamine (0.56 mg/kg, s.c.) pretreatment abolished nicotine-paired lever responding for all compounds. In a separate cohort, male and female Sprague-Dawley rats underwent CCI surgery and tested for CCI-induced mechanical allodynia via the von Frey assay. Each compound produced CCI-induced mechanical allodynia reversal. RTI-36 displayed higher potency than either RTI-102 or RTI-76. These novel epibatidine analogs may prove to be useful tools in the fight against nicotine dependence as well as novel neuropathic pain analgesics
Recommended from our members
Discovery of a mammalian splice variant of myostatin that stimulates myogenesis
Myostatin plays a fundamental role in regulating the size of skeletal muscles. To date, only a single myostatin gene and no splice variants have been identified in mammals. Here we describe the splicing of a cryptic intron that removes the coding sequence for the receptor binding moiety of sheep myostatin. The deduced polypeptide sequence of the myostatin splice variant (MSV) contains a 256 amino acid N-terminal domain, which is common to myostatin, and a unique C-terminus of 65 amino acids. Western immunoblotting demonstrated that MSV mRNA is translated into protein, which is present in skeletal muscles. To determine the biological role of MSV, we developed an MSV over-expressing C2C12 myoblast line and showed that it proliferated faster than that of the control line in association with an increased abundance of the CDK2/Cyclin E complex in the nucleus. Recombinant protein made for the novel C-terminus of MSV also stimulated myoblast proliferation and bound to myostatin with high affinity as determined by surface plasmon resonance assay. Therefore, we postulated that MSV functions as a binding protein and antagonist of myostatin. Consistent with our postulate, myostatin protein was
co-immunoprecipitated from skeletal muscle extracts with an MSV-specific antibody. MSV over-expression in C2C12 myoblasts blocked myostatin-induced Smad2/3-dependent signaling, thereby confirming that MSV antagonizes the
canonical myostatin pathway. Furthermore, MSV over expression increased the abundance of MyoD, Myogenin and MRF4 proteins (P,0.05), which indicates that MSV stimulates myogenesis through the induction of myogenic regulatory factors. To help elucidate a possible role in vivo, we observed that MSV protein was more abundant during early post-natal muscle development, while myostatin remained unchanged, which suggests that MSV may promote the growth of skeletal muscles. We conclude that MSV represents a unique example of intra-genic regulation in which a splice variant directly antagonizes the biological activity of the canonical gene product
A randomised Phase II trial of Hydroxychloroquine and Imatinib versus Imatinib alone for patients with Chronic Myeloid Leukaemia in Major Cytogenetic Response with residual disease
In chronic-phase chronic myeloid leukaemia (CP-CML), residual BCR-ABL1+ leukaemia stem cells are responsible for disease persistence despite TKI. Based on in vitro data, CHOICES (CHlorOquine and Imatinib Combination to Eliminate Stem cells) was an international, randomised phase II trial designed to study the safety and efficacy of imatinib (IM) and hydroxychloroquine (HCQ) compared with IM alone in CP-CML patients in major cytogenetic remission with residual disease detectable by qPCR. Sixty-two patients were randomly assigned to either arm. Treatment âsuccessesâ was the primary end point, defined as â„0.5âlog reduction in 12-month qPCR level from trial entry. Selected secondary study end points were 24-month treatment âsuccessesâ, molecular response and progression at 12 and 24 months, comparison of IM levels, and achievement of blood HCQ levels >2000âng/ml. At 12 months, there was no difference in âsuccessâ rate (pâ=â0.58); MMR was achieved in 80% (IM) vs 92% (IM/HCQ) (pâ=â0.21). At 24 months, the âsuccessâ rate was 20.8% higher with IM/HCQ (pâ=â0.059). No patients progressed. Seventeen serious adverse events, including four serious adverse reactions, were reported; diarrhoea occurred more frequently with combination. IM/HCQ is tolerable in CP-CML, with modest improvement in qPCR levels at 12 and 24 months, suggesting autophagy inhibition maybe of clinical value in CP-CML
Evaluating holistic needs assessment in outpatient cancer care--a randomised controlled trial: the study protocol
Introduction People living with and beyond cancer are vulnerable to a number of physical, functional and psychological issues. Undertaking a holistic needs assessment (HNA) is one way to support a structured discussion of patientsâ needs within a clinical consultation. However, there is little evidence on how HNA impacts on the dynamics of the clinical consultation. This study aims to establish (1) how HNA affects the type of conversation that goes on during a clinical consultation and (2) how these putative changes impact on shared decision-making and self-efficacy. Methods and analysis The study is hosted by 10 outpatient oncology clinics in the West of Scotland and South West England. Participants are patients with a diagnosis of head and neck, breast, urological, gynaecological and colorectal cancer who have received treatment for their cancer. Patients are randomised to an intervention or control group. The control group entails standard careâroutine consultation between the patient and clinician. In the intervention group, the patient completes a holistic needs assessment prior to consultation. The completed assessment is then given to the clinician where it informs a discussion based on the patient's needs and concerns as identified by them. The primary outcome measure is patient participation, as determined by dialogue ratio (DR) and preponderance of initiative (PI) within the consultation. The secondary outcome measures are shared decision-making and self-efficacy. It is hypothesised that HNA will be associated with greater patient participation within the consultation, and that shared decision-making and feelings of self-efficacy will increase as a function of the intervention. Ethics and dissemination This study has been given a favourable opinion by the West of Scotland Research Ethics Committee and NHS Research & Development. Study findings will be disseminated through peer-reviewed publications and conference attendanc
Challenges of Annotation and Analysis in Computer-Assisted Language Comparison: A Case Study on Burmish Languages
The use of computational methods in comparative linguistics is growing in popularity. The increasing deployment of such methods draws into focus those areas in which they remain inadequate as well as those areas where classical approaches to language comparison are untransparent and inconsistent. In this paper we illustrate specific challenges which both computational and classical approaches encounter when studying South-East Asian languages. With the help of data from the Burmish language family we point to the challenges resulting from missing annotation standards and insufficient methods for analysis and we illustrate how to tackle these problems within a computer-assisted framework in which computational approaches are used to pre-analyse the data while linguists attend to the detailed analyses
Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche.
Age at menarche is a marker of timing of puberty in females. It varies widely between individuals, is a heritable trait and is associated with risks for obesity, type 2 diabetes, cardiovascular disease, breast cancer and all-cause mortality. Studies of rare human disorders of puberty and animal models point to a complex hypothalamic-pituitary-hormonal regulation, but the mechanisms that determine pubertal timing and underlie its links to disease risk remain unclear. Here, using genome-wide and custom-genotyping arrays in up to 182,416 women of European descent from 57 studies, we found robust evidence (Pâ<â5âĂâ10(-8)) for 123 signals at 106 genomic loci associated with age at menarche. Many loci were associated with other pubertal traits in both sexes, and there was substantial overlap with genes implicated in body mass index and various diseases, including rare disorders of puberty. Menarche signals were enriched in imprinted regions, with three loci (DLK1-WDR25, MKRN3-MAGEL2 and KCNK9) demonstrating parent-of-origin-specific associations concordant with known parental expression patterns. Pathway analyses implicated nuclear hormone receptors, particularly retinoic acid and Îł-aminobutyric acid-B2 receptor signalling, among novel mechanisms that regulate pubertal timing in humans. Our findings suggest a genetic architecture involving at least hundreds of common variants in the coordinated timing of the pubertal transition
Upregulation of the stress-associated gene p8 in mouse models of demyelination and in multiple sclerosis tissues
Cuprizone-induced demyelination is a mouse model of multiple sclerosis (MS) as cuprizone-fed mice exhibit neuroin-flammation and demyelination in the brain. Upon removal of cuprizone from the diet, inflammation is resolved and reparative remyelination occurs. In an Affymetrix Gene-Chip analysis, the stress-associated gene p8 was strongly upregulated (>10Ă) during cuprizone-induced demyelination but not remyelination. We verified this upregulation (>15Ă) of p8 in the CNS during demyelination by real-time polymerase chain reaction (PCR). This upregulation is brain-specific, as p8 is not elevated in the liver, lung, kidney, spleen, and heart of cuprizone-treated mice. We also localized the cellular source of p8 during cuprizone treatment, and further found elevated expression during embryogenesis but not in normal adult brain. Compared with wild-type controls, the death of oligodendrocytes in p8â/â mice is delayed, as is microglial recruitment to areas of demyelination. The corpus callosum of p8â/â mice demyelinates at a slower rate than wild-type mice, suggesting that p8 exacerbates CNS inflammation and demyelination. Enhanced expression of p8 is also observed in the spinal cords of mice with acute experimental autoimmune encephalomyelitis (EAE) induced by PLP139â151 peptide (10Ă). Increased expression is detected during disease onset and expression wanes during the remission phase. Finally, p8 is found upregulated (8Ă) in post-mortem tissue from MS patients and is higher in the plaque tissue compared with adjacent normal-appearing white and gray matter. Thus, p8 is an excellent candidate as a novel biomarker of demyelination
Importance of Human Leukocyte Antigen (HLA) Class I and II Alleles on the Risk of Multiple Sclerosis
Multiple sclerosis (MS) is a complex disease of the central nervous system of unknown etiology. The human leukocyte antigen (HLA) locus on chromosome 6 confers a considerable part of the susceptibility to MS, and the most important factor is the class II allele HLA-DRB1*15:01. In addition, we and others have previously established a protective effect of HLA-A*02. Here, we genotyped 1,784 patients and 1,660 healthy controls from Scandinavia for the HLA-A, HLA-B, HLA-C and HLA-DRB1 genes and investigated their effects on MS risk by logistic regression. Several allele groups were found to exert effects independently of DRB1*15 and A*02, in particular DRB1*01 (ORâ=â0.82, pâ=â0.034) and B*12 (including B*44/45, ORâ=â0.76, pâ=â0.0028), confirming previous reports. Furthermore, we observed interaction between allele groups: DRB1*15 and DRB1*01 (multiplicative: ORâ=â0.54, pâ=â0.0041; additive: APâ=â0.47, pâ=â4Ă10â06), DRB1*15 and C*12 (multiplicative: ORâ=â0.37, pâ=â0.00035; additive: APâ=â0.58, pâ=â2.6Ă10â05), indicating that the effect size of these allele groups varies when taking DRB1*15 into account. Analysis of inferred haplotypes showed that almost all DRB1*15 bearing haplotypes were risk haplotypes, and that all A*02 bearing haplotypes were protective as long as they did not carry DRB1*15. In contrast, we found one class I haplotype, carrying A*02-C*05-B*12, which abolished the risk of DRB1*15. In conclusion, these results confirms a complex role of HLA class I and II genes that goes beyond DRB1*15 and A*02, in particular by including all three classical HLA class I genes as well as functional interactions between DRB1*15 and several alleles of DRB1 and class I genes
- âŠ